2-乙氧乙基三苯基溴化鏻 | 25361-69-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-乙氧乙基三苯基溴化鏻
• 英文名称: (2-ethoxyethyl)triphenylphosphonium bromide
• 英文别名: 2-ethoxyethyl(triphenyl)phosphanium;bromide
• CAS: 25361-69-7
• 化学式: Br*C₂₂H₂₄OP
• 分子量: 415.31
• InChiKey: SXPXVPGJBRZVLW-UHFFFAOYSA-M

物化性质

• 熔点：
  182 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.02
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-6-((5R,7S)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-1,2,3,4-tetrahydronaphthalene-2-carbaldehyde 、 2-乙氧乙基三苯基溴化鏻 在 potassium tert-butylate 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 19.0h， 以8.93 g的产率得到(5R,7S)-7-((R)-6-((Z)-3-ethoxyprop-1-en-1-yl)-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one
  参考文献：
  名称：

  [EN] SUBSTITUTED BICYCLIC COMPOUNDS
  [FR] COMPOSÉS BICYCLIQUES SUBSTITUÉS

  摘要：

  揭示了Formula（I）、（II）、（III）、（IV）和（V）及/或其盐的化合物，其中R1为OH或OP（O）（OH）2，X1、X2、X3、R2、R2a、Ra、Rb和Rc在此处有定义。还揭示了将这些化合物用作选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展方面是有用的，如自身免疫疾病和血管疾病。

  公开号：

  WO2016028959A1
• 作为产物：
  描述：

  三苯基膦 以 乙醇 为溶剂， 生成 2-乙氧乙基三苯基溴化鏻
  参考文献：
  名称：

  消除和加成反应。第十九部分。从β-取代的乙基苯基醚中消除酚盐：1,2-消除中活化的性质

  摘要：

  在对消除反应中活化性质的研究中，测量了碱性条件下一系列X-CH 2 ·CH 2 ·OPh类型的17种苯基醚中苯氧化物的消除速率。

  DOI：

  10.1039/j29700000671

文献信息

• SUBSTITUTED BICYCLIC COMPOUNDS
  申请人：Bristol-Myers Squibb Company

  公开号：US20160052888A1

  公开（公告）日：2016-02-25

  Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R 1 is —OH or —OP(O)(OH) 2 , and X 1 , X 2 , X 3 , R 2 , R 2a , R a , R b , and R c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P 1 , and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  公开了公式（I）、（II）、（III）、（IV）和（V）的化合物及/或其盐，其中R1为—OH或—OP（O）（OH）2，X1、X2、X3、R2、R2a、Ra、Rb和Rc的定义如本文所述。还公开了使用这些化合物作为选择性G蛋白偶联受体S1P1激动剂的方法，以及包括这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或障碍方面有用，例如自身免疫性疾病和血管疾病。
• Substituted bicyclic compounds
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10166249B2

  公开（公告）日：2019-01-01

  Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  所公开的是式 (I)、(II)、(III)、(IV) 和 (V) 的化合物： 和/或其盐，其中 R1 是-OH 或-OP(O)(OH)2，X1、X2、X3、R2、R2a、Ra、Rb 和 Rc 在本文中定义。还公开了将此类化合物用作 G 蛋白偶联受体 S1P1 选择性激动剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗、预防或减缓各种治疗领域的疾病或失调，如自身免疫性疾病和血管疾病。
• Thyroid hormone analogs. Synthesis of 3'-substituted 3,5-diiodo-L-thyronines and quantitative structure-activity studies of in vitro and in vivo thyromimetic activities in rat liver and heart
  作者：Paul D. Leeson、David Ellis、John C. Emmett、Virendra P. Shah、Graham A. Showell、Anthony H. Underwood

  DOI：10.1021/jm00396a008

  日期：1988.1

  Twenty-nine novel 3'-substituted derivatives of the thyroid hormone 3,3',5-triiodo-L-thyronine (T3) have been synthesized by using established methods and by a new route involving manipulation of a 3'-formyl intermediate. In vitro hormone receptor binding (to intact nuclei) and in vivo thyromimetic activity (induction of mitochondrial 3-phosphoglycerate oxidoreductase, GPDH) were measured in rat liver and heart for these new analogues and for the 18 previously reported 3'-substituted 3,5-diiodo-L-thyronines. Analysis of the binding data using theoretical conformational and quantitative structure-affinity methods implies that the 3'-substituent recognition site on the thyroid hormone receptor is hydrophobic and limited in depth to the length of the natural iodo substituent, but has sufficient width to accommodate a phenyl or cyclohexyl group. Receptor binding is reduced by approximately 10-fold in 3'-acyl derivatives which form strong intramolecular acceptor hydrogen bonds with the adjacent 4'-hydroxyl. The compounds studied showed no differences in their relative affinities for heart and liver nuclei, suggesting that receptors in these tissues are similar. However, the relationships between thyromimetic activity (induction of GPDH) and nuclear binding showed some tissue differences. A high correlation between activity and binding is observed for full agonists in the heart, but an equally significant correlation for the liver data is only seen when 3'-substituent bulk (molar refractivity) is included in the analysis. These results suggest the possibility that differential tissue penetration or access to receptors may occur in vivo.
• Cristau, Henri-Jean; Bottaro, Denis; Plenat, Francoise, Phosphorus and Sulfur and the Related Elements, 1982, vol. 14, p. 63 - 72
  作者：Cristau, Henri-Jean、Bottaro, Denis、Plenat, Francoise、Pietrasanta, Francine、Christol, Henri

  DOI：——

  日期：——
• Cristau, Henri-Jean; Mouchet, Patrick, Phosphorus, Sulfur and Silicon and the Related Elements, 1995, vol. 107, # 1-4, p. 135 - 144
  作者：Cristau, Henri-Jean、Mouchet, Patrick

  DOI：——

  日期：——